From: Does a selective non-peptide angiotensin II type 2 receptor agonist reduce post-infarction left ventricular remodeling?
LVEF (%)
LVEDV (μl)
LVESV (μl)
SV (μl)
MASS (mg)
Control (n = 17)
27.5 ± 10.5
74.1 ± 26.7
54.8 ± 24.8
19.2 ± 6.4
47.5 ± 13.9
C21 (n = 23)
27.3 ± 11.8
91.6 ± 23.8
66.9 ± 21.5
24.7 ± 13.3
56.7 ± 15.2
p value
0.98
<0.01
<0.05